Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Routine tests during follow-up of patients after primary treatment for operable breast cancer
Annals of Oncology, Volume 6, No. 8, Year 1995
Notification
URL copied to clipboard!
Description
Summary: Background: Follow-up tests for patients after diagnosis and primary treatment of breast cancer are routinely performed. However, the usefulness of these follow-up parameters remains unclear. We determined the yield of a variety of blood tests used to detect the presence of overt metastatic diseaseMethods: 4105 patients enrolled in International (Ludwig) Breast Cancer Study Group (IBCSG) randomized clinical trials from 1978 to 1985 were analyzed for abnormal or equivocal findings in six routine blood tests obtained every 3 months for the first two years, every six months for years 3-5 and yearly thereafter. The relationship of test results to the occurrence of overt metastatic disease was evaluated. The relapses were categorized as follows in order to estimate the yield of the different tests for relevant sites of metastases: any breast cancer relapse, bone ± other; liver ± otherResults: Alkaline phosphatase alone was abnormal in a high proportion of patients with either bone metastases, liver metastases, or both. SGOT and gamma-GT were also sensitive for patients with liver metastases. Bilirubin, serum calcium, and serum creatinine were relatively insensitive indicators of relapse. Abnormal test results were reported sometime during a patient's disease-free period for 3% to 6% of patients, depending on the testConclusions: Alkaline phosphatase was the most effective blood test to distinguish patients with relapse from those without relapse. It is inexpensive and its yield is relatively high for predicting liver and bone metastases. The routine use of the other tests analyzed to detect metastases was not justified © 1995 Kluwer Academic Publishers.
Authors & Co-Authors
Crivellari, Diana
Italy, Aviano
Irccs Centro Di Riferimento Oncologico Aviano
Price, Karen N.
United States, Amherst
Ibcsg Statistical and Data Management Centers
Hagen, M.
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Goldhirsch, Aaron
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Gelber, Richard D.
United States, Amherst
Ibcsg Statistical and Data Management Centers
Castiglione, Monica M.
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Switzerland, Bern
Ibcsg Coordinating Center
Coates, Alan S.
Switzerland, Bern
Ibcsg Coordinating Center
Rudenstam, Carl Magnus
United States, Amherst
Ibcsg Statistical and Data Management Centers
Collins, John Paxton
Switzerland, Bern
Ibcsg Coordinating Center
Lindtner, Jurij
Slovenia, Ljubljana
Onkološki Inštitut Ljubljana
Cortés-Funés, Hernán
Spain, Madrid
Madrid Breast Cancer Group
Gudgeon, Anne
South Africa, Observatory
Groote Schuur Hospital
Simoncini, Edda Lucia
United Kingdom, London
The Royal Free Hospital
Byrne, Michael J.J.
Switzerland, Bern
Ibcsg Coordinating Center
Schniirch, H. G.
Germany, Essen
Universitätsklinikum Essen
Fey, Martin F.
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Tattersall, Martin H.N.
Switzerland, Bern
Ibcsg Coordinating Center
Forbes, John Frederick
Switzerland, Bern
Ibcsg Coordinating Center
Cavalli, Francesco G.
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Reed, Richard G.
Switzerland, Bern
Ibcsg Coordinating Center
Senn, Hansjörg
Germany, Dusseldorf
Heinrich-heine-universität Düsseldorf
Statistics
Citations: 21
Authors: 21
Affiliations: 9
Identifiers
Doi:
10.1093/oxfordjournals.annonc.a059314
ISSN:
09237534
Research Areas
Cancer
Health System And Policy
Study Design
Randomised Control Trial
Cohort Study